Introduction to the management of hemophilia
============================================

Hemophilia A is an X-linked bleeding disorder that results from insufficient levels of factor VIII (FVIII) coagulant activity and is characterized by a prolonged clotting time, most often measured by the activated partial thromboplastin time. Patients with severe disease (FVIII levels \<1%) may present with spontaneous bleeding into joints, muscles, internal organs, or subsequent to trauma or surgery. Such bleeding episodes, if left untreated, result in serious complications including permanent, disabling joint, muscle, and nerve damage, loss of musculoskeletal function, or even death ([@b3]; [@b23]). Over the last century, hemostatic therapy for hemophilia A has evolved from using whole blood transfusion to that of highly purified plasma-derived FVIII (pdFVIII) concentrates, and in the last 15 years, recombinant FVIII (rFVIII) concentrates. With each advancement in therapy, the quality of life for affected individuals has improved.

FVIII concentrates are commonly used on-demand (to treat bleeding episodes), prophylactically (planned regular infusions for prevention or suppression of bleeding episodes or utilized to interrupt a bleeding pattern), and to provide hemostatic coverage during and after surgical procedures. With each generation of FVIII concentrates, new features have been introduced to improve pathogen safety and convenience. Advancements in therapy have made patients less dependent on treatment centers and provided them increased control of their disorder ([@b14]).

A major complication in hemophilia management today is the development of inhibitors, antibodies that neutralize the infused FVIII. Inhibitors most often emerge within the first 50 exposure days (ED) of replacement therapy in patients with severe hemophilia A ([@b28]). Although inhibitor incidence greatly decreases after this initial high-risk period, the risk does not reach zero and persists to some small degree throughout life ([@b28]). The immunogenicity of new clotting factor concentrates is evaluated in studies with previously treated patients (PTPs) that have demonstrated tolerance to FVIII through an extensive history of prior exposure to licensed products (ie, 100--150 previous ED) without inhibitor development ([@b54]).

In contrast, the rate of inhibitor development in previously untreated patients (PUPs) or minimally transfused patients is approximately 25%--30% ([@b33]). Studies and registries of various sizes and rigor in PTPs, who have demonstrated tolerance to FVIII therapies, have reported an inhibitor incidence of 1%--3% ([@b29]).

Inhibitor kinetics and persistence vary; they are measured and quantified by the Bethesda assay ([@b27]) in the form of Bethesda units (BU). An estimated 20%--55% of all inhibitors disappear spontaneously without specific intervention; these inhibitors tend to be low titer and are defined as transient. Inhibitors that persist are divided into two main categories based upon the highest BU level achieved; low titer inhibitors are those that have titers \<5BU despite repeated exposure to FVIII concentrate whereas high responding inhibitors are those whose historical titer is ≥5BU and often rise after repeat exposure, a phenomenon called anamnesis. Patients with low titer inhibitors are often continued with FVIII concentrates in doses sufficient to achieve a hemostatic level and control bleeding ([@b13]). Patients with higher titer inhibitors may become tolerant to FVIII following treatment on immune tolerance programs often utilizing prolonged periods of intensive FVIII therapy ([@b56]). In some cases, however, immune tolerance is either not utilized or fails, and the inhibitor persists indefinitely; these patients are most often treated with bypassing therapies, agents that achieve hemostasis through alternative mechanisms to obtain bleed control. Bypassing agents, although highly effective in treating bleeding episodes, are not uniformly effective, leaving this population at risk of increased morbidity and mortality ([@b4]).

History of pathogen transmission and the need for blood-free recombinant FVIII technology
=========================================================================================

The pathogen transmission safety record of factor concentrates used to manage hemophilia continues to be a major concern both for those receiving and prescribing these therapies. In the 1980s, many people with hemophilia were infected with HIV and/or hepatitis C (HCV) through the use of contaminated plasma derived clotting factor concentrates. As a result, the life-span for those with hemophilia who contracted these blood borne pathogens was negatively impacted, increasing their morbidity and mortality ([@b2]). Today, an estimated 30% of people with hemophilia between the ages of 21--60 years are infected with HIV ([@b2]). As a consequence, a number of safety measures including enhanced donor screening tests and procedures, and the introduction of viral inactivation and removal technologies, have been implemented to address blood-borne disease in plasma based therapies. The desire for therapies with the highest degree of safety has remained a driving force in therapeutic research and development. As a result, a variety of rFVIII products have been developed as safer alternatives to prevent transmission of potential emerging pathogens.

In 2006, the FDA released a statement that the risk of acquiring variant Creutzfeld-Jakob Disease (vCJD) is low, but could not be deemed to be zero, in people using US-licensed pdFVIII products ([@b20]). Based on these conclusions, the Great Lakes Hemophilia Foundation (GLHF) recommended that physicians and patients consider this risk when choosing an appropriate therapy ([@b37]). To this end, the National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC) also recommended recombinant FVIII products as the treatment of choice for patients with hemophilia A ([@b36]). The UK Department of Health independently created a "Recombinant for All" policy to ensure that hemophilia patients have access to the safest treatments ([@b52]). Similar policies are now in effect in a number of countries, including Austria, Germany, Ireland, the Netherlands, Australia, and Canada ([@b1]; [@b15]; [@b39]).

To date, there have not been any documented viral- or prion-based disease transmission reports from rFVIII products ([@b14]). Despite the excellent safety record of rFVIII therapeutics, the risk for potential transmission of blood-borne infectious agents through the use of human- or animal-derived plasma proteins in rFVIII concentrates remained a concern. No current viral inactivation/elimination method, such as solvent/detergent methods or heat treatment, is infallible ([@b9]; [@b14]; [@b32]). For example, three viruses are known to be a potential threat to the supply of blood and blood products; hepatitis A (HAV) is resistant to the solvent/detergent viral inactivation step, parvovirus B is both heat and solvent/detergent resistant, and transfusion transmitted virus (TTV) is resistant to heat, detergent, and disinfectants ([@b52]). Despite the present use of effective pathogen inactivation methods, international guidelines recommend that manufacturers make all efforts to remove human and animal proteins, including human albumin and other plasma-derived proteins, from the manufacturing process of recombinant products, and that such differences be taken into consideration when selecting an appropriate therapy ([@b14]; [@b52]; [@b14]).

Nearly all rFVIII concentrates use human- or animal-derived plasma proteins at some point in the processing. Recombinant FVIII concentrates now are classified into first, second, and third generation based on the use of human- or animal-derived materials at various stages of processing, as shown in [Table 1](#tbl1){ref-type="table"}.

###### 

Commercial recombinant FVIII therapies

  Generation   Product                                          Producing cell line   Culture medium                         Molecular FVIII    Product stablizer
  ------------ ------------------------------------------------ --------------------- -------------------------------------- ------------------ -------------------
  First        Recombinate^®^                                   CHO                   Bovine serum albumin                   Full-length        Human albumin
  Second       Kogenate^®^ FS[b](#tf1-2){ref-type="table-fn"}   BHK                   HPPS[a](#tf1-1){ref-type="table-fn"}   Full-length        Sucrose
  Second       Helixate^®^ FS[b](#tf1-2){ref-type="table-fn"}   BHK                   HPPS[a](#tf1-1){ref-type="table-fn"}   Full-length        Sucrose
  Second       ReFacto^®^                                       CHO                   Human serum albumin                    B-domain deleted   Sucrose
  Third        ADVATE^®^                                        CHO                   None                                   Full-length        Trehalose

CHO indicates Chinese hamster ovary cell line; BHK indicates Baby hamster kidney cell line. Information as indicated in respective product package inserts.

HPPS, Human plasma protein solution consists of several human plasma proteins, including albumin.

The equivalent products Kogenate FS and Helixate FS are also marketed under the brand names Kogenate Bayer and Helixate Nexgen, respectively.

The first-generation product relies on plasma proteins in the production, purification, and final formulation of the product ([@b26]; Package Insert, Recombinate^®^, Baxter BioScience). Second-generation products use plasma-derived proteins in the production and/or purification phase (Package Insert Kogenate^®^ FS, Bayer Healthcare; Package Insert ReFacto^®^, Wyeth Pharmaceuticals, Inc), and trace levels of such proteins have been detected in the final container of selected products ([@b18]; EPAR Kogenate Bayer; EPAR Helixate NexGen). In 2003, ADVATE^®^ (Antihemophilic Factor \[Recombinant\], Plasma/Albumin-Free Method \[rAHF-PFM\]) was licensed as the first rFVIII that does not include animal or human plasma protein additives during the cell culture, purification, or formulation processes. The clinical experience of this full-length rFVIII is the focus of this article.

Development of the plasma/albumin-free platform
===============================================

To develop ADVATE^®^, the Chinese hamster ovary (CHO) cell line used to produce the first-generation FVIII concentrate, Recombinate^®^, was adapted to grow in a proprietary culture medium, free of human and animal derived additives. This cell line, which co-expresses full-length FVIII and von Willebrand Factor (VWF), did not undergo any genetic manipulations, and the cDNA coding sequence of the recombinant proteins remained identical to those used for Recombinate^®^. To attain consistent and stable production of rFVIII, a continuous (chemostat) perfusion bioreactor culture is used to harvest the clotting factor with minimal environmental changes to the cell line.

The purification techniques utilized for ADVATE^®^ are based on the methods used for its first generation predecessor. First, the rFVIII-containing cell culture medium is filtered to remove the CHO cells, followed by a sterile filtration step. The rFVIII protein is then purified in a stepwise fashion, using multiple chromatography columns, including immunoaffinity (to eliminate non-FVIII proteins) and cation exchange (using electrical charge differences to eliminate other impurities). This is followed by a solvent/detergent (S/D) step, a viral inactivation process which preserves the integrity of the structure and function of the FVIII molecule yet inactivates lipid enveloped infectious agents ([@b25]). Following the S/D step, the eluate is further purified using anion exchange chromatography. Finally, ADVATE^®^ is pooled, frozen, and stored until ready for final formulation, filling, and lyophilization.

The absence of human- or animal-plasma protein additives eliminates the risk of pathogen transmission. Formulation components including the sugars trehalose and mannitol mimic the stabilizing function of albumin and have been substituted to replace plasma protein stabilizers ([@b46]).

Preclinical evaluation
======================

Biochemical and preclinical analyses assessed toxicity, tolerability, and hemostatic activity of ADVATE^®^. The new formulation was compared with its well-established predecessor, Recombinate^®^ ([@b8]; [@b54]), demonstrating that ADVATE^®^ and Recombinate^®^ have structural and functional equivalence ([@b19]).

The approved route of administration for ADVATE^®^ is via intravenous bolus infusion; however, in specific clinical circumstances such as surgery or severe or life-threatening bleeding events, FVIII products are administered via continuous infusion ([@b5]). Therefore, the stability and feasibility of ADVATE^®^ delivery by continuous infusion were assessed in in vitro experiments that simulated this clinical application ([@b21]). In the presence and absence of heparin (2 U/mL), ADVATE^®^ at mid- (522 IU/vial) and high-potency (1210 IU/vial) doses, were run through a CADD-1 infusion pump at a rate of 1.5 mL/minute, at 30 °C, for 48 hours. Reconstituted control vials of the same lot were maintained at the same temperature, over the same duration. Stability and recovery of at least 80% of baseline potency was observed for up to 48 hours after reconstitution and running through the CADD-1 infusion pump at room temperature (30 °C) both in the presence and absence of added heparin ([@b21]). Additional stability tests regarding the storage conditions of unreconstituted ADVATE^®^ were also performed and will be discussed in the "Patient perspectives" section.

Clinical study program
======================

Five completed clinical trials have investigated the use of ADVATE^®^ in the prevention and treatment of bleeding episodes in PTPs. [Table 2](#tbl2){ref-type="table"} illustrates the studies, patients, and endpoints measured in these completed phase II/III clinical studies.

###### 

Global clinical program of ADVATE^®^

  Study (n)                                           Endpoints
  --------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Pivotal (108)                                       Pharmacokinetics, efficacy, safety and immunogenicity in PTPs
  Continuation[a](#tf2-1){ref-type="table-fn"} (82)   Long-term pharmacokinetics, efficacy, safety and immunogenicity in PTPs who completed the Pivotal study
  Surgery[a](#tf2-1){ref-type="table-fn"} (59)        Efficacy and safety in PTPs undergoing surgical/invasive procedures
  Pediatric (53)                                      Pharmacokinetics, efficacy, safety and immunogenicity in PTPs \<6 years old
  Japanese Registry (15)                              Pharmacokinetics, efficacy, safety and immunogenicity in PTPs in Japan

Patients were eligible to participate in more than one study

**Abbreviations**: PTPs, previously treated patients.

Pivotal efficacy and safety study
=================================

Results from a three-part study investigating the use of ADVATE^®^ in 10- to 65-year-old PTPs without previous or detectable inhibitors have previously been reported ([@b19]). Double-blinded, randomized, crossover pharmacokinetic (PK) evaluations compared pilot-scale ADVATE^®^ (produced in Orth, Austria) with both commercial-scale ADVATE^®^ (produced in Neuchatel, Switzerland) and with Recombinate^®^. Fifty-six subjects were randomized to Part 1 of the study comparing PK parameters of ADVATE^®^ with Recombinate^®^. Subjects with severe or moderately severe hemophilia A (baseline FVIII level ≤2%) received an initial infusion (50 ± 5 IU/kg) of either ADVATE^®^ or Recombinate^®^ with analysis post-infusion per ISTH guidelines out to 48 hours. Following a wash-out period, subjects received a second infusion of the opposite product at a dose identical to the first infusion administered. Mean post-infusion plasma FVIII activity profiles were almost identical across all time points ([Figure 1](#fig1){ref-type="fig"}), and the authors concluded bioequivalence in terms of area under the curve (AUC) and adjusted recovery.

![PK comparisons of Recombinate^®^ and ADVATE^®^. Post-infusion factor VIII levels (logarithmically adjusted for illustrative purposes) over time were similar with R-FVIII and ADVATE^®^. Data shown represent the natural logarithm FVIII activity (Ln) as a function of time in hours (h). Reprinted with permission from [@b19]. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. *Haemophilia*, 10:428--37. Copyright © 2004 Blackwell Publishing.](vhrm0305-555-01){#fig1}

Part 2 of the study was an open-label assessment of the efficacy, safety, and immunogenicity of ADVATE^®^. One hundred and eight subjects (baseline FVIII level ≤2%) followed a standard fixed prophylactic regimen over a period of at least 75 ED. The study product was infused while the subject was in a steady (non-bleeding) state, 3--4 infusions/week at a dose of 25--40 IU/kg, with the specific dose prescribed by the investigator and rounded up to the nearest whole vial. While on this treatment regimen, 30% of subjects (n = 32) did not experience a breakthrough bleeding episode, while 54% of the 510 bleeding episodes (n = 274) occurred in 70% of subjects (n = 75). In a post-hoc analysis, the overall bleed rate was correlated inversely with the degree of compliance with the prescribed prophylactic regimen. Subjects who were infused with ≤25 IU/kg per dose of ADVATE^®^ for more than 20% of prophylactic infusions, and/or those who administered less than three infusions per week for more than 20% of the study (n = 37), experienced a 2.3-fold higher rate of bleeding when compared to subjects who complied with the prescribed prophylactic regimen, infusing at least 80% of the time with the appropriate prescribed dose (n = 70; p\< 0.03). Of the 510 bleeding episodes that occurred during the study, 93% were resolved with 1--2 infusions of ADVATE^®^, and 86% were rated as Excellent/Good hemostatic response.

Part 3 was a double-blind, randomized, cross-over comparison of the pharmacokinetics of pilot-scale prepared ADVATE^®^ with commercial-scale prepared ADVATE^®^ to confirm bioequivalence of the product produced via two scales, pilot versus commericial. On completion of Part 2, 55 subjects were randomly assigned to receive an initial study infusion of either pilot-scale or commercial-scale ADVATE^®^ at a dose of 50 ± 5 IU/kg. Following a wash-out period, subjects received a second infusion of the product produced from the other facility. The authors concluded that the products from the two facilities were bioequivalent ([@b19]).

Of the 108 subjects who received ADVATE^®^ during this study, one subject developed a low-level titer (2.0 BU), non-persistent inhibitor that was not detectable at an 8-week follow up visit. In addition, of the 867 adverse experiences (AE) categorized as non-serious, only 19, reported in 7 subjects, were judged to be possibly (n = 12) or probably (n = 7) related to the administration of ADVATE^®^. The 19 non-serious, related AEs consisted of taste perversion (n = 3), headache (n = 2), fever (n = 1), diarrhea (n = 1), dizziness (n = 3), hot flashes (n = 2), abdominal pain (n = 1), lower chest pain (n = 1), shortness of breath (n = 1), sweating (n = 1), nausea (n = 1), rigors (n = 1), and itching at the infusion site (n = 1). No subject withdrew due to an AE related to the study product. None of the serious AEs were regarded as possibly or probably related to study medications ([@b19]).

Long-term efficacy and safety
=============================

The long-term efficacy and safety of ADVATE^®^ in PTPs with severe or moderately severe hemophilia A (baseline FVIII level ≤2%) and no previous or detectable FVIII inhibitors were evaluated in an open-label, two-part continuation study of subjects who completed the pivotal phase III ADVATE^®^ study ([@b19]). The pharmacokinetics and safety profile of a single infusion of ADVATE^®^ (50 ± 5 IU/kg) in subjects was compared before and after ≥75 ED to ADVATE^®^. Safety, immunogenicity, and hemostatic efficacy of ADVATE^®^ of three different therapeutic regimens were evaluated: standard prophylaxis of 25--40 IU/kg, 3--4 times a week; modified prophylaxis as determined by the investigator; and on-demand therapy ([@b22]). No clinically relevant differences were detected between pharmacokinetic parameters measured at the initiation of trial product and after ≥75 EDs in either the per-protocol (n = 22) or the intent-to-treat populations (n = 34).

Eleven of 81 subjects reported no bleeding episodes, and all 11 were on a prophylactic treatment regimen for ≥90% of Part 2. Seventy of 81 subjects experienced 822 bleeding episodes, of which 820 were treated; 88.5% of the treated bleeding episodes were managed with one or two infusions. As shown in [Figure 2](#fig2){ref-type="fig"}, annual bleed rates for patients on standard prophylaxis (n = 54), modified prophylaxis (n = 53), or on-demand treatment (n = 9) were 6.0, 4.8, and 18.5, respectively. Protocol-compliant subjects on standard prophylaxis experienced lower annual bleed rates (n = 30, 4.5 bleeds/year) compared with non-compliant subjects (n = 24, 7.9 bleeds/year). Hemostatic efficacy outcomes were sustained throughout a median participation interval of 617.5 days ([@b22]).

![Mean annual total bleed episode rate per regimen. Subjects on prophylactic regimens experienced fewer bleeding episodes than those using on-demand treatment.](vhrm0305-555-02){#fig2}

No subjects developed a detectable inhibitor during the continuation study. After a combined total of 20,832 infusions, 79 of 82 subjects reported a total of 506 AEs. Four AEs, none of which were serious, were classified to be at least possibly related to the product, for an overall rate of 0.02% related AEs (4 AEs/20,832 infusions). Three of these were considered mild (headache, dysgeusia, and elevated liver function tests), and one moderate (moderately severe migraine). Of the 11 serious AEs reported by seven subjects, none was considered related to ADVATE^®^ treatment. The authors concluded that pharmacokinetic parameters and the safety profile of ADVATE^®^ were stable with long-term use ([@b22]).

Efficacy during surgical, dental, or other invasive procedures
==============================================================

Medical management during surgery is complicated for patients with hemophilia due to the need to attend to hemostatic control. Surgery is commonly used to address complications resulting from repeated bleeding into joints and muscles. Surgery may also be required to address general medical issues as experienced in the non-hemophilic population. Management of hemostasis during surgical procedures requires the establishment and maintenance of appropriate target FVIII levels to prevent bleeding both during the operative, post-operative, and rehabilitative phases. Treatment regimens typically involve pre-, intra-, and post-operative administration of FVIII during hospitalization and continued replacement therapy following discharge dependent upon the length of hospitalization and the procedure performed.

The safety and hemostatic efficacy of ADVATE^®^ in PTPs (≥150 ED) undergoing surgical, dental, or other invasive procedures was assessed in a multicenter, prospective, open-label, uncontrolled surgery study. Severe or moderately severe hemophilia A subjects (baseline FVIII level ≤2%) greater than 5 years of age without history or presence of an inhibitor were eligible to participate and were allowed to enroll repeatedly for distinct surgical procedures. Each procedure was counted individually ([@b38]).

A total of 58 subjects underwent 65 procedures. Procedures were classified as either major (moderate to critical risk and/or estimated blood loss ≥500 mL), minor (mild risk and/or estimated blood loss \<500 mL), or dental. ADVATE^®^ was administered by continuous infusion in 18 procedures (4 major, 14 minor) and by bolus infusion in 47 procedures (18 major, 21 minor, and 8 dental). Blood loss was less than or within the expected range compared to a normal individual undergoing the same procedure in 55 of 58 assessed procedures, as determined by the surgeon. Intra- and postoperative hemostatic efficacy was rated "Excellent" or "Good" in 100% (n = 61 and 62, respectively) of assessed procedures ([@b38]).

No serious AEs related to ADVATE^®^ were reported during this study. Eight non-serious AEs were considered at least possibly related to ADVATE^®^: 2 mild AEs (lymphangitis and pruritus), 4 moderate AEs (one decreased hematocrit, one hemorrhage at time of drain removal, and 2 cases of edema at surgical site), and 2 severe (decreased coagulation FVIII coincident with a central venous access device-related infection and hematoma at surgical site). No patient developed an inhibitor during this study ([@b38]).

Efficacy and safety in children
===============================

The pharmacokinetics, efficacy, safety, and immunogenicity of ADVATE^®^ in PTPs less than 6 years of age with severe or moderately severe hemophilia A (baseline FVIII level ≤2%) were evaluated in a pediatric PTP study. This open-label, multi-center, prospective, uncontrolled, two-part study evaluated the use of ADVATE^®^ in 53 children (mean age 3.1 ± 1.5 years) with previous FVIII history of at least 50 EDs, and without a history of an inhibitor. Part 1 consisted of a modified pharmacokinetic evaluation following a single 50 IU/kg infusion of ADVATE^®^. Part 2 evaluated the efficacy, immunogenicity, and safety of ADVATE^®^ in pediatric PTPs while on standard prophylaxis (25--50 IU/kg, 3--4 times/week), investigator-modified prophylaxis, or on-demand therapy, as prescribed by the investigating physician. Mean plasma terminal phase half-life (9.88 ± 1.89 h) and adjusted in vivo recovery (1.90 ± 0.43 IU/dL per IU/kg) were lower in these young children compared to the adult population in the pivotal trial. These differences may have been influenced by methodology, including a delayed first time point in the pediatric patients (1 hour post-infusion), which is beyond the maximum peak level derived in many adult subjects in the pivotal trial. However, these differences may also have been impacted by physiological differences between young children and adults, as these differences were positively correlated with age and body mass index in the pediatric patients ([@b7]; [@b12]).

Bleeding episodes were infrequent in children on prophylaxis, possibly due to less underlying joint disease compared to their adult counterparts enrolled in the previously described trials. The majority (90.1%) of the 354 bleeding episodes were managed with one or two infusions of ADVATE^®^, and treatment efficacy was rated as "Excellent" or "Good" for 93.8% of the bleeding episodes ([@b7]).

Participants received a combined total of 7980 infusions of ADVATE^®^ over a median of 156 exposure days (range: 14--384 days). During the study, six AEs in two subjects were considered to be related to ADVATE^®^, all of which were non-serious. No inhibitors were detected ([@b7]).

Perioperative management in children
====================================

The complexity of hemostatic management during surgery in children is compounded by challenges related to limited venous access and differing pharmacokinetic patterns such as decreased half-life and lower AUC, C~max~, and recovery compared with adults ([@b7]).

Efficacy and safety data of ADVATE^®^ in pediatric (\<16 years of age) PTPs undergoing surgical procedures were collected ([@b49]) from the surgery and pediatric studies described herein. The subjects had no inhibitors and underwent elective or emergency surgical, dental, or an otherwise invasive procedure. Some individual subjects enrolled multiple times for separate surgical interventions; each procedure was counted individually. The study product was administered per each study site's investigator-determined standard of care for surgical management of hemophilia patients. Patients could be treated via bolus injection or continuous infusion, and continuous infusion could be supplemented with bolus injections as needed. Procedures were classified as either major or minor as defined previously.

A total of 18 patients underwent 19 procedures: 2 major, 1 moderate, 13 minor, and 3 dental procedures. Sixteen procedures used one or more bolus injections, and 3 used continuous infusion with supplemental bolus injections. Intra-operative efficacy was rated as "Excellent" or "Good" in 100% (n = 14) of the assessed procedures. Postoperative efficacy was rated as "Excellent" or "Good" in 100% (n = 15) of the assessed procedures ([@b49]). As shown in [Table 3](#tbl3){ref-type="table"}, 13 of 14 evaluable procedures had less than, or were within the predicted blood loss range for an unaffected individual undergoing the procedure. Although one patient was reported to experience greater than predicted blood loss in one procedure, no supplemental blood or blood products were required to maintain hemostasis ([@b49]).

###### 

Predicted and actual blood loss associated with surgical procedures

  -------------------------------------------------------------------------------------------------
  Procedure                                    Actual blood loss (mL)   Average-maximum\
                                                                        Predicted blood loss (mL)
  -------------------------------------------- ------------------------ ---------------------------
  Ross procedure                               50                       200--2000

  Axillary mass excision                       50                       N/D

  Arthroscopie knee synovectomy                50                       50--250

  Port-a-cath removal                          100                      15--50

  Port-a-cath removal and excision of seroma   8                        5--10

  Elbow synovectomy                            20                       30--100

  Inferior oblique myectomy                    0                        0.5--1.0

  Arthroscopic ankle synovectomy/debridement   5                        10--50

  Radionuclide ankle synovectomy               0                        0

  Dental extraction                            15                       5--15

  Multiple teeth extraction (a)                5                        5--10

  Multiple teeth extraction (b)                7                        20

  Eye cyst excision                            1                        2

  Central catheter removal (a)                 5                        5

  Central catheter removal (b)                 20                       15--20
  -------------------------------------------------------------------------------------------------

N/D, Not documented.

This case series highlights some key surgical scenarios encountered in the pediatric management of hemophilia. Known differences in pharmacokinetic parameters between children and adults have been documented ([@b7]; [@b19]); however, the hemostatic assessment results of this study closely reflect the surgical experience reported in PTPs between 7 and 65 years of age most likely due to attention to these differences through monitoring of levels achieved ([@b38]).

In this evaluation of pediatric patients, a total of 349 ADVATE^®^ infusions were administered to PTPs \<16 years old. Six serious AEs were reported, none of which were related to the product. Ninety-seven non-serious AEs were reported, of which one was judged as related to the product (mild pruritus). No inhibitors were detected, and no subject withdrew due to an AE ([@b49]).

Summary of clinical data
========================

Based on data from the completed clinical studies, ADVATE^®^ has been shown to be efficacious, well-tolerated, and non-immunogenic in adult and pediatric PTPs with hemophilia A. When used prophylactically, on-demand, as well as perioperatively, ADVATE^®^ was effective in preventing and/or controlling bleeding events ([@b19]; [@b7]; [@b22]; [@b38]; [@b49]). As expected, annual bleed rates were lower in subjects using ADVATE^®^ prophylactically, especially in those adherent to prescribed regimens, compared to an on-demand treatment regimen ([@b19]; [@b22]).

The comprehensive clinical program for ADVATE^®^ is illustrated in [Figure 3](#fig3){ref-type="fig"}. This current report focuses on the completed studies in large cohorts of patients. Future work will focus on the ongoing Phase IV studies investigating dose responses, prophylactic outcomes, and comparative surgical outcomes in PTPs, as well as use in PUPs.

![Global clinical program study plan. Five Phase II/III clinical studies have been completed (dark bars), while four additional Phase IV studies are in progress as of 2007 (hatched bars).](vhrm0305-555-03){#fig3}

Safety and tolerability
=======================

The risk of inhibitor development with ADVATE^®^ has been evaluated in a broad range of therapeutic settings and in patient groups that represent somewhat different inhibitor risk profiles. Data compiled from 5 completed clinical trials and registries include 208 unique PTPs, 198 of which had ≥10 ED and/or 6 months of observation during the study. Of these, one low-titer, non-persistent inhibitor was detected in one subject, for an overall incidence rate of 0.51% (95% confidence interval 0.03%--2.91%) (Unpublished data, Baxter BioScience). An on-going prospective post-licensure safety surveillance study designed to evaluate the first full year experience of new patients on ADVATE^®^ will continue to accumulate data regarding the immunogenicity in a larger hemophilia population, including patients with mild or moderate hemophilia A, as well as patients with a history of inhibitor development. Thus, this study may provide a more accurate estimate of the incidence of inhibitors in real world practice.

Inhibitor management
====================

Immune tolerance induction (ITI) in patients with inhibitors has been reported to be successful in a number of cases using ADVATE^®^. In one study, 3 PUPs (13--16 months of age) who developed inhibitors while on ADVATE^®^ (1 low titer inhibitor patient and 2 high titer inhibitor patients) were successfully tolerized using ADVATE^®^ ([@b47]). A follow-up chart review of 9 children (≤23 months old) who developed inhibitors on various recombinant products documented the use of ADVATE^®^ for ITI ([@b52]). This report included 5 patients with low titer inhibitors (≤5 BU), 3 patients with high titer inhibitors (\>5 BU) and 1 patient with a very high titer inhibitor (peak titer 1823 BU). The inhibitors were successfully eradicated in 8 of the 9 patients. Despite aggressive ITI, the inhibitor persisted in the patient with very high titer. No AEs were reported during this treatment period ([@b52]).

Patient perspectives
====================

Hemophilia care has shifted from the paradigm of hospital or clinic based treatment of bleeding events to home based therapy utilizing diverse regimens ranging from on-demand to primary prophylaxis to immune tolerance induction ([@b48]). Prophylaxis as a long-term treatment regimen requires FVIII infusions 2--4 times per week and has been documented to be the best therapy for prevention of joint disease associated with musculoskeletal hemorrhage ([@b6]). Such a treatment regimen requires not only a commitment by the patient and/or caregiver, but requires safe and readily available infusion products; many of these previous barriers to prophylaxis have been addressed by the introduction of recombinant products. In addition to potential improvements in musculoskeletal outcomes, prophylaxis may also improve the psychosocial development of children by eliminating the anticipatory concern associated with potential future bleeding events ([@b6]).

FVIII concentrates that eliminate the risk of pathogen transmission not only increase patient confidence in the safety of the product but may also have long-term economical benefits as well. Pharmacoeconomic models of medical costs associated with co-morbidities suggest that hemophilia patients with HIV and HCV have higher medical costs compared to non-infected hemophilia patients due to increased hospitalization, more frequent office visits to physicians and specialists, and use of long-term health resources ([@b11]; [@b11]). Although these scenarios are specific to HIV and HCV, it can be hypothesized that similar pharmacoeconomic findings might be applicable with possible emerging pathogens causing a chronically infected state. Thus, the use of therapies least likely to cause infectious co-morbidity may lead to avoidance cost-savings.

Patient convenience
===================

To make home treatment practical coagulation products have been improved to make them more convenient, easier to use, and stable for longer periods of time under a variety of storage conditions. In addition, needle-less reconstitution devices have been developed for all rFVIII products. Such devices decrease the risk of patient or caregiver injury.

Because patients today are less reliant on hemophilia treatment centers, manufacturers have improved the stability and portability of rFVIII products to accommodate patients' lifestyles. The US prescribing information for ADVATE^®^ states that the lyophilized product should be stored under refrigeration (2--8 °C \[36--46 °F\]), but it may be stored at room temperature (up to 30 °C C\[86 °F\]) for a period of up to six months, not exceeding the expiration date (Package Insert, ADVATE^®^). To test real-world treatment situations, additional in vitro analyses demonstrated that ADVATE^®^ remains stable beyond the recommended duration of storage ([@b44]). Samples were stored for 2 weeks at 40 °C prior to being stored at 5, 25, or 30 °C for up to 24 months, and the activity was measured at 88.9%, 85.7%, and 83.5% of initial activity, respectively ([@b44]). Likewise, when cycled three times through room temperature and refrigerated storage, the stability of ADVATE^®^ was maintained ([@b44]). Although not recommended by the manufacturer, these studies support the stability profile of ADVATE^®^.

Discussion
==========

In response to the needs of the hemophilia community, ADVATE^®^ was developed as the first third-generation hemophilia product with a safety and efficacy profile comparable with Recombinate^®^ (R-FVIII, Baxter BioScience). The removal of blood-based additives from the entire manufacturing process eliminates the risk of blood borne disease transmission associated with such additives. All clinical trials completed to date demonstrate that ADVATE^®^ is effective in adult and pediatric PTPs for the management of hemophilia A. As part of the continuing clinical program, four additional Phase IV studies are ongoing: 1) a PUP study, evaluating the pharmacokinetic parameters, efficacy, and safety profile of the product in previously untreated patients less than 6 years of age; 2) a dose response study, investigating the effect of 3 doses of ADVATE^®^ on major pharmacokinetic parameters in PTPs with severe hemophilia A; 3) a prophylaxis study, comparing the efficacy, safety and immunogenicity of ADVATE^®^ in PTPs with moderately severe to severe hemophilia A during standard prophylaxis, alternate modified prophylaxis, and on-demand regimens; and 4) a randomized surgery study comparing the efficacy and safety of ADVATE^®^ when administered by continuous or bolus infusion during the intra- and post-operative setting of PTPs undergoing total knee replacement.

The availability of safe, effective, and convenient genetically engineered FVIII therapies has the potential to improve patient compliance and therefore enhance the quality of life for people living with hemophilia A.
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